Middle East and Africa Human Vaccines Market Research Report Information, by Technology (Attenuated, Inactivated, Toxoid, Conjugate, & Subunit, Recombinant DNA), Disease Indication (Pneumococcal, Influenza, Hepatitis, Rotavirus, DTP, Polio, others), by Type (Prophylactic and Therapeutic); by Composition (Mono Vaccine and Combination Vaccines) by End User (children and adults) and by Route of Administration (Oral, Injectable And Other) - Forecast till 2030

Human Vaccines Market Overview

The human vaccines market reached a valuation of USD 2.8 billion in 2015, it will reach a value of USD 0.98 billion and a CAGR of 5.90% in the forecast period 2023 to 2030.

The emergence of infectious diseases is leading the biotech company to enhance the development of vaccines. The research and development activities for vaccines are driving the market. The support from the government for vaccine development and focus on immunization is another factor driving the market. The heavy capital investments by private and public organizations for low purchasing power in developing countries may restrain the market growth.

The travel rates have increased far greater distances, and people living in densely populated areas get closer contact with wild animals. Due to this, the rate of infectious diseases has increased. This has also led to global epidemics. For decades many infectious diseases such as avian flu, swine flu, Zika, SARS, MERS, Ebola, chikungunya, and most recently was, COVID-19 - SARS-CoV-2. This has led to the market’s developments. The concern for infectious diseases has increased in recent years, and the demand for vaccines is propelling. The growing emergence of new diseases enhances the research and development activities and funding initiatives, which will propel the market in the forecast period.

Study Objectives Middle East and Africa Human Vaccines Market:

• To provide detail analysis of the market structure along with forecast for the next 6 years of various segments and sub-segments of the Middle East and Africa human vaccines market.


• To provide insights about factors affecting the market growth.


• To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.


• To provide past and estimated future revenue of the market’s segments and sub-segments with respect to the Middle East and Africa human vaccines market.


• To provide country level analysis of the market with respect to the current market size and future growth prospect.


• To provide country level analysis of the market for segments which includes by technology, by disease indication, by type, by composition, by end user, by route of administration and other sub segments. To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the market


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments globally.

Middle East and Africa Human Vaccines Market, by Technology, 2015 (%)

Intended Audience

• Vaccines manufacturers


• Vaccines suppliers


• Private research laboratories


• Research and development (R&D) companies


• Market research and consulting service providers


• Government research laboratories


• Contract manufacturing organizations

Key Players for Middle East and Africa Human Vaccines Market:

Some of the key players in this market are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others.Recent Development

In May 2022

Kenya Healthcare Federation, the Health Sector Board of Kenya Private Sector Alliance (KEPSA), has praised the government for securing the deal for the Moderna vaccine. This will lead to the set up of a USD 500 million manufacturing facility in Kenya. This will produce 500 million doses of mRNA vaccines each year.

In May 2022

Intravacc B.V. is a global leader in translational research and the development of preventive and therapeutic vaccines. The company has announced an agreement with Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd in China for Avacc 3, which is an OMV-based whooping cough vaccine. 

According to the agreement, Zhifei Lvzhu will receive the license for the Chinese territory and Africa, South America, and Asian countries. Intravacc will receive benchmark and upfront payments over net sales. The companies will continue to collaborate to tailor the Avacc 3 concept vaccine in territories, including toxicology, upscaling, and clinical trials.

Segments:

Middle East and Africa human vaccines market has been segmented on the basis of technology which comprises attenuated, inactivated, toxoid, conjugate & subunit, recombinant DNA. On the basis of disease indication; market is segmented into pneumococcal, influenza, hepatitis, rotavirus, DTP, polio and others. On the basis of type the market is segmented into prophylactic and therapeutic. On the basis of composition market is again segmented into mono vaccine and combination vaccines. The route of administration segments the market into oral, injectable and other. Moreover on the basis of end user; market is segmented into children and adults.

Regional Analysis of Middle East and Africa Human Vaccines Market:

Depending on geographic region, human vaccine market is segmented into several countries: UAE is the largest market for human vaccines in the entire Middle East and Africa human vaccines market closely followed by Egypt. The rest of Africa’s market especially Sub Saharan regions are however the fastest growing market with a huge unmet medical needs.